Provided Prurisol shows positive results and therefore acquires value, a good Regeneron-like option would be to sell off Prurisol and use the proceeds to clinically advance both Brilacidin and Kevetrin and maximize their value. I believe IPIX has hinted at this strategic desire in the past. I like that plan, even if IPIX gets only high 8 or low 9 digits for their psoriasis candidate.